(MedPage Today) — The investigational drug daraxonrasib, now available through an early access program, demonstrated promising efficacy in previously treated pancreatic ductal adenocarcinoma (PDAC) and was associated with high-grade adverse events…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
